Reducing gap between two doses of Covishield is being considered: Sources

Reducing the gap between two doses of Covishield is being considered and it will be discussed in the National Technical Advisory Group on Immunisation in India (NTAGI), official sources said

Covishield
Covishield coronavirus vaccine | Photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Aug 26 2021 | 9:52 PM IST

Reducing the gap between two doses of Covishield is being considered and it will be discussed in the National Technical Advisory Group on Immunisation in India (NTAGI), official sources said on Thursday.

Chairman of India's COVID-19 Working Group of NTAGI, Dr N K Arora, however, said no such proposal for changing the dose interval for any COVID-19 vaccine is under consideration.

"There are several studies and programmatic data collection processes are on to assess the vaccine effectiveness. NTAGI is reviewing the vaccine effectiveness data on a regular basis. Currently there is no proposal for change in the dose interval for Covishield, Covaxin and Sputnik V is under consideration," Arora said.

The government in May had further extended the gap between the two doses of Covishield from 6-8 weeks to 12-16 weeks and said the decision to increase the gap was based on scientific evidence.

Based on emerging data, India would revisit the dosage interval for Covishield vaccine and take appropriate action, Arora had earlier said.

On the decision to increase the gap between two doses of Covishield from four-six weeks to 12-16 weeks, he had said the move was based on scientific decision and there was no dissenting voice among members of the National Technical Advisory Group on Immunisation (NTAGI).

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineVaccination

First Published: Aug 26 2021 | 9:52 PM IST

Next Story